Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity

Experimental Neurology

Volumn 266, Issue , 2015, Pages 99-111

  Kunze, Reiner ^a   Urrutia, Andrés ^a   Hoffmann, Angelika ^b   Liu, Hui ^a   Helluy, Xavier ^b   Pham, Mirko ^b   Reischl, Stefan ^a   Korff, Thomas ^a   Marti, Hugo H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Blood brain barrier; Dimethyl fumarate; Edema; Ischemia; Nrf2; Stroke

Indexed keywords

CADHERIN; CLAUDIN 5; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUMARIC ACID DIMETHYL ESTER; GELATINASE A; GELATINASE B; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OCCLUDIN; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN TISSUE; CELL MIGRATION; CELLULAR DISTRIBUTION; CEREBRAL ENDOTHELIAL CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STABILITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; GCLC GENE; GELATINOLYTIC ACTIVITY; GENE TARGETING; GO 1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MULTIPLE SCLEROSIS; NEWBORN; NONHUMAN; NRF2 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION STATE; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANIMAL; C57BL MOUSE; CELL MOTION; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANIMALS, NEWBORN; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; CELL MOVEMENT; FUMARATES; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; RNA, SMALL INTERFERING; STROKE; TIGHT JUNCTIONS;

EID: 84923918043     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.02.022     Document Type: Article

References (62)

1. Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., Stevens M., Fischer R., Carmeliet P., Maxwell P.H., Pugh C.W., Frizzell N., Soga T., Kessler B.M., El-Bahrawy M., Ratcliffe P.J., Pollard P.J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20:524-537.
2. Albrecht P., Bouchachia I., Goebels N., Henke N., Hofstetter H.H., Issberner A., Kovacs Z., Lewerenz J., Lisak D., Maher P., Mausberg A.K., Quasthoff K., Zimmermann C., Hartung H.P., Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation 2012, 9:163.
3. Ashrafian H., Czibik G., Bellahcene M., Aksentijevic D., Smith A.C., Mitchell S.J., Dodd M.S., Kirwan J., Byrne J.J., Ludwig C., Isackson H., Yavari A., Stottrup N.B., Contractor H., Cahill T.J., Sahgal N., Ball D.R., Birkler R.I., Hargreaves I., Tennant D.A., Land J., Lygate C.A., Johannsen M., Kharbanda R.K., Neubauer S., Redwood C., de Cabo R., Ahmet I., Talan M., Gunther U.L., Robinson A.J., Viant M.R., Pollard P.J., Tyler D.J., Watkins H. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012, 15:361-371.
4. Aslam M., Ahmad N., Srivastava R., Hemmer B. TNF-alpha induced NFkappaB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 2012, 57:269-275.
5. Bauer A.T., Burgers H.F., Rabie T., Marti H.H. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J. Cereb. Blood Flow Metab. 2010, 30:837-848.
6. Benardais K., Pul R., Singh V., Skripuletz T., Lee D.H., Linker R.A., Gudi V., Stangel M. Effects of fumaric acid esters on blood-brain barrier tight junction proteins. Neurosci. Lett. 2013, 555:165-170.
7. Chen H., Assmann J.C., Krenz A., Rahman M., Grimm M., Karsten C.M., Kohl J., Offermanns S., Wettschureck N., Schwaninger M. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J. Clin. Invest. 2014, 124:2188-2192.
8. Coisne C., Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid. Redox Signal. 2011, 15:1285-1303.
9. Correale J., Villa A. Cellular elements of the blood-brain barrier. Neurochem. Res. 2009, 34:2067-2077.
10. Dang J., Brandenburg L.O., Rosen C., Fragoulis A., Kipp M., Pufe T., Beyer C., Wruck C.J. Nrf2 expression by neurons, astroglia, and microglia in the cerebral cortical penumbra of ischemic rats. J. Mol. Neurosci. 2012, 46:578-584.
11. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22:391-397.
12. Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., Gold R., Linker R.A. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 2011, 6:e16172.
13. Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent T.A., Savitz S.I., Lo E.H. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250.
14. Forster C., Burek M., Romero I.A., Weksler B., Couraud P.O., Drenckhahn D. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 2008, 586:1937-1949.
15. Fox R.J., Miller D.H., Phillips J.T., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser M.T., Viglietta V., Dawson K.T. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012, 367:1087-1097.
16. Gerdes S., Shakery K., Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br. J. Dermatol. 2007, 156:838-842.
17. Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., Tornatore C., Sweetser M.T., Yang M., Sheikh S.I., Dawson K.T. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012, 367:1098-1107.
18. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Grone H.J., Hammerling G.J., Arnold B., Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
19. Hill J.W., Poddar R., Thompson J.F., Rosenberg G.A., Yang Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012, 220:277-290.
20. Itoh K., Tong K.I., Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 2004, 36:1208-1213.
21. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K.T., Sandrock A.W., O'Neill G.N. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472.
22. Kaur C., Ling E.A. Blood brain barrier in hypoxic-ischemic conditions. Curr. Neurovasc. Res. 2008, 5:71-81.
23. Korff T., Braun J., Pfaff D., Augustin H.G., Hecker M. Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. Blood 2008, 112:73-81.
24. Kunze R., Zhou W., Veltkamp R., Wielockx B., Breier G., Marti H.H. Neuron-specific prolyl-4-hydroxylase domain 2 knockout reduces brain injury after transient cerebral ischemia. Stroke 2012, 43:2748-2756.
25. Lakhan S.E., Kirchgessner A., Tepper D., Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 2013, 4:32.
26. Lee D.H., Gold R., Linker R.A. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int. J. Mol. Sci. 2012, 13:11783-11803.
27. Lehner C., Gehwolf R., Tempfer H., Krizbai I., Hennig B., Bauer H.C., Bauer H. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid. Redox Signal. 2011, 15:1305-1323.
28. Li W., Kong A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 2009, 48:91-104.
29. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Bruck W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
30. Liu W.Y., Wang Z.B., Zhang L.C., Wei X., Li L. Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci. Ther. 2012, 18:609-615.
31. Loewe R., Holnthoner W., Groger M., Pillinger M., Gruber F., Mechtcheriakova D., Hofer E., Wolff K., Petzelbauer P. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 2002, 168:4781-4787.
32. Lopez-Ramirez M.A., Fischer R., Torres-Badillo C.C., Davies H.A., Logan K., Pfizenmaier K., Male D.K., Sharrack B., Romero I.A. Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells. J. Immunol. 2012, 189:3130-3139.
33. Marti H.H., Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15809-15814.
34. Montesano R., Pepper M.S., Mohle-Steinlein U., Risau W., Wagner E.F., Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990, 62:435-445.
35. Mrowietz U., Christophers E., Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol. 1998, 138:456-460.
36. Mrowietz U., Christophers E., Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br. J. Dermatol. 1999, 141:424-429.
37. Obermeier B., Daneman R., Ransohoff R.M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013, 19:1584-1596.
38. Ooi A., Wong J.C., Petillo D., Roossien D., Perrier-Trudova V., Whitten D., Min B.W., Tan M.H., Zhang Z., Yang X.J., Zhou M., Gardie B., Molinie V., Richard S., Tan P.H., Teh B.T., Furge K.A. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20:511-523.
39. Plaschke K., Staub J., Ernst E., Marti H.H. VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp. Neurol. 2008, 214:285-292.
40. Pun P.B., Lu J., Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic. Res. 2009, 43:348-364.
41. Reischl S., Li L., Walkinshaw G., Flippin L.A., Marti H.H., Kunze R. Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLoS ONE 2014, 9:e84767.
42. Rostami Yazdi M., Mrowietz U. Fumaric acid esters. Clin. Dermatol. 2008, 26:522-526.
43. Sandoval K.E., Witt K.A. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 2008, 32:200-219.
44. Scannevin R.H., Chollate S., Jung M.Y., Shackett M., Patel H., Bista P., Zeng W., Ryan S., Yamamoto M., Lukashev M., Rhodes K.J. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341:274-284.
45. Schilling S., Goelz S., Linker R., Luehder F., Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 2006, 145:101-107.
46. Schoch H.J., Fischer S., Marti H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002, 125:2549-2557.
47. Shah Z.A., Li R.C., Thimmulappa R.K., Kensler T.W., Yamamoto M., Biswal S., Dore S. Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience 2007, 147:53-59.
48. Shih A.Y., Li P., Murphy T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci. 2005, 25:10321-10335.
49. Simard J.M., Kent T.A., Chen M., Tarasov K.V., Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007, 6:258-268.
50. Srivastava S., Alfieri A., Siow R.C., Mann G.E., Fraser P.A. Temporal and spatial distribution of Nrf2 in rat brain following stroke: quantification of nuclear to cytoplasmic Nrf2 content using a novel immunohistochemical technique. J. Physiol. 2013, 591:3525-3538.
51. Tanaka N., Ikeda Y., Ohta Y., Deguchi K., Tian F., Shang J., Matsuura T., Abe K. Expression of Keap1-Nrf2 system and antioxidative proteins in mouse brain after transient middle cerebral artery occlusion. Brain Res. 2011, 1370:246-253.
52. Vandermeeren M., Janssens S., Borgers M., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 1997, 234:19-23.
53. Vandermeeren M., Janssens S., Wouters H., Borghmans I., Borgers M., Beyaert R., Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J. Invest. Dermatol. 2001, 116:124-130.
54. Wallbrecht K., Drick N., Hund A.C., Schon M.P. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp. Dermatol. 2011, 20:980-985.
55. Wang C.X., Shuaib A. Critical role of microvasculature basal lamina in ischemic brain injury. Prog. Neurobiol. 2007, 83:140-148.
56. Wang Y., Kilic E., Kilic U., Weber B., Bassetti C.L., Marti H.H., Hermann D.M. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 2005, 128:52-63.
57. Weis S.M., Cheresh D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437:497-504.
58. Wierinckx A., Breve J., Mercier D., Schultzberg M., Drukarch B., Van Dam A.M. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 2005, 166:132-143.
59. Wilms H., Sievers J., Rickert U., Rostami-Yazdi M., Mrowietz U., Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 2010, 7:30.
60. Wunder A., Schoknecht K., Stanimirovic D.B., Prager O., Chassidim Y. Imaging blood-brain barrier dysfunction in animal disease models. Epilepsia 2012, 53(Suppl. 6):14-21.
61. Yang Y., Candelario-Jalil E., Thompson J.F., Cuadrado E., Estrada E.Y., Rosell A., Montaner J., Rosenberg G.A. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 2010, 112:134-149.
62. Zhao Y., Rempe D.A. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J. Cereb. Blood Flow Metab. 2011, 31:1412-1423.